Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc,
A Luciferase-Expressing Pancreatic Cancer Cell Line
(Pages: 212-214)
Faculty of Pharmaceutical Sciences, Nagasaki International University, Huis Ten Bosch, Sasebo, Nagasaki, Japan
Department of Genome Editing, Institute of Biomedical Science, Kansai Medical University, Shin-machi, Hirakata City, Osaka, Japan
Tanaka Hiromitsu,
Nishida-Fukuda Hisayo,
Wada Morimasa,
Tokuhiro Keizo,
Matsushita Hiroaki,
Ando Yukio.
Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc,
A Luciferase-Expressing Pancreatic Cancer Cell Line.
Cell J .
2022 ;
24 (4 ): 212 -214 .
Abstract
HASPIN acts in chromosome segregation via histone phosphorylation. Recently, HASPIN inhibitors have been shown to suppress growth of various cancer cells. Pancreatic cancer has no symptom in the early stages and may progress before detection. So, the 5-year survival rate is low. Here, we reported that administration of the HASPIN inhibitor, CHR-6494, to mice bearing pancreatic BxPC-3-Luc cancer cells significantly suppressed growth of BxPC-3-Luc cells. CHR-6494 might be a useful agent for treating pancreatic cancer.